Obviously all talk from the company as of late has been regarding partnership. My ears prick up when I hear you mention buyout.
I know you're not a big speculator on deal valuations. Would you indulge us on what you feel could be pulled on a buyout at this time? I won't ask you to tell me yours without telling you mine.
I'm thinking the following:
With the loss of Prurisol and apparent disinterest in ABSSSI, we'd probably be looking at a buyout in the $300 million to $500 million range with upside to $700 million if the buyer is particularly interested in Kevetrin.